There is capital sitting on the sidelines, but founders and CEOs should realize that investors are digging into their due diligence. The “wow” factor and potential size of the medtech market matter much less now than solid fundamentals.
Experts point out some pitfalls that medtech companies should be aware of when trying to raise capital.
To achieve success, a medical device startup must build a sophisticated data architecture specifically designed to deliver maximum value for its customers’ use cases. However, it’s extremely difficult to build such an architecture—especially given early-stage budget constraints. That’s why startups must wisely synch their data architecture spending with their funding rounds.
Among the many lessons from the COVID-19 pandemic, it’s clear that the future of healthcare belongs to those who can harness science and technology—sometimes rapidly—to improve population health through more efficient and accessible care.
The collective variables within the healthcare system make it difficult to guarantee device security all the time.
All industries under the healthcare umbrella should embrace each other’s capabilities because no single category of player can master it and bring to consumers all that we need and demand, says Stephen Bernstein of McDermott Will & Emery.
While companies developing solutions that address the current pandemic may be receiving an influx of financial support, recovery for companies in other segments of the industry is slow.
The immense challenges posed by the coronavirus pandemic are fueling interest in cloud computing among vaccine researchers, clinicians, healthcare companies and patients across Asia.
The outlook for 2020 and beyond is positive, but medical device companies must continue to evolve their technologies and partnerships to keep the attention of investors.
Peter Micca of Deloitte discusses the changes that are happening within the healthcare ecosystem as a whole.